5.2
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
View/Download PDF

Translate this page into:

Original article
12 (
8
); 2457-2463
doi:
10.1016/j.arabjc.2015.01.016

Terbium sensitized luminescence for the determination of fexofenadine in pharmaceutical formulations

Sultan Qaboos University, College of Science, Box 36, Department of Chemistry, Al-Khod 123, Oman

⁎Corresponding author. Fax: +968 24415469. alkindy@squ.edu.om (Salma M.Z. Al-Kindy)

Disclaimer:
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.

Peer review under responsibility of King Saud University.

Abstract

A sensitive and specific luminescence method for the determination of Fexofenadine (FEX), in pharmaceutical formulations is reported. The method is based on the sensitization of terbium (Tb3+) by complex formation with FEX. The luminescence signal for Tb–FEX complex is greatly enhanced by the addition of triethylamine (ET3N) and zinc nitrate in methanol solution. Monitoring of the signal is accomplished when the instrument is in the phosphorescence mode with the excitation and emission wavelengths set at λex = 220 nm and λem = 550 nm respectively. Optimum conditions for the formation of the complex in methanol were 2.25 × 10−6 M of Tb3+, 5.00 × 10−6 M of Et3N and Zn2+ which allows for the determination of 10–800 ppb of FEX in the batch mode with a detection limit of 0.3 ppb. The proposed method was successfully applied for the determination of FEX in pharmaceutical formulations.

Keywords

Fexofenadine
Terbium
Sensitized luminescence
Drug formulations
1

1 Introduction

Fexofenadine (FEX), (±)-4-[1-hydroxy-4-(4-hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α,α-dimethyl benzene acetic acid (Fig. 1), is a non-cardiotoxic second-generation histamine H1-receptor antagonist in piperidine-class drugs used to treat hay fever symptoms. It does not cause sedation or other central nervous system effects because it does not cross the blood–brain barrier (Simpson and Jarvis, 2000).

Chemical structure of fexofenadine.
Figure 1 Chemical structure of fexofenadine.

Fexofenadine does not have a negative effect on the psychomotor efficiency. The substance has anti-inflammatory characteristics, which presents a modern approach to allergy therapy. Besides, fexofenadine may prove a safer alternative in the treatment of asthma and atopic dermatitis (Meeves and Appajosyula, 2003; Kawashima and Hirodi, 2007) and is rapidly absorbed with a long duration of action, making it suitable for once daily administration.

Several analytical methods have been reported for the analysis of FEX in biological fluids and pharmaceutical formulations. These methods include high performance liquid chromatography (HPLC) (Uno et al., 2004; Pankaniya et al., 2013; Krakus et al., 2008), capillary electrophoresis (Breier et al., 2005; Mikus et al., 2005), mass spectrometric methods (Guo et al., 2010; Hofmann et al., 2002), spectrophotometric methods (Gazy et al., 2002; Naravana and Veena, 2010; Ashour et al., 2013), and chemiluminescence (CL) method (Al-Lawati et al., 2011).

Recently, the use of spectrofluorimetric techniques for the quantification of FEX was reported. The determinations were carried out using indirect methods such as fluorescence quenching (Alothman et al., 2010) and derivatization techniques (Eid and Wahba, 2012; Ibrahim et al., 2011). The native fluorescence of FEX occurs in the ultraviolet region, which may be subjected to interference with the matrix. However, the drug contains a carboxylic acid group, which is known to form complexes with many metals such as Tb3+ and Eu3+. The complexes absorb energy at the characteristic wavelength of the ligand and emit radiation at the characteristic wavelength of the lanthanide ions (Ln (III). Lanthanide ions are characterized by low luminescence quantum yields due to their weak molar absorptivity. However, the quantum yields are tremendously enhanced by chelating the lanthanides with suitable organic ligands that have broad intense absorption bands. The excited state of the ligand, transfers energy intramolecularly to the emitting level of the Ln (III) ion and thus serves as an antenna chromophore.

As part of our continuous efforts on developing methods on drug analysis (Al-Kindy and Suliman, 2007; Al-Kindy et al., 2007, 2004, 2012, 2008), we report a novel luminescence method based on the enhancement and sensitization of terbium brought about by complexation with FEX. Determination of FEX after complexation with europium was recently reported (AbdEl-Hay et al., 2012). However, the signal was monitored by fluorescence technique, which was accompanied by scattering due to second order emission. Herein we report an improved method based on sensitized time resolved luminescence of terbium in the presence of Zn2+ and Et3N. To our knowledge, this is the first time that the effect of Zn2+ and Et3N on co-luminescence agent is investigated in a carboxylic acid system. The luminescence properties were investigated in various solvents. Factors affecting complexation such as the concentration of Tb3+ and the ratio of Tb3+ to FEX as well as the effect of co-ligands and co-luminescence agents on the luminescence properties of FEX–Tb3+ have been carefully studied. The method was subsequently used to determine the concentration of FEX in pharmaceutical samples. Our experimental results were validated by a fluorimetric method.

2

2 Experimental

2.1

2.1 Apparatus

Luminescence measurements were performed using Perkin Elmer LS-55 luminescence spectrometer (Perkin Elmer, Beaconsfield UK) equipped with a xenon discharge flash lamp. The operation and data processing were controlled by the fluorescence Data Manager Software. The excitation and emission wavelengths were set at 220 nm and 550 nm respectively. The instrument was operated in a phosphorescence mode with a gate time of 0.04 ms and a delay time of 0.2 ms used throughout the measurements. Absorption spectra were recorded on a Varian CARY 50 Conc UV visible spectrophotometer (Connecticut, USA) with 1 cm matched quarts cell.

2.2

2.2 Reagents

HPLC grade methanol, ethanol, 1-propanol, acetone and acetonitrile were purchased from Sigma–Aldrich (St Louis, Mo, USA). Terbium (III) chloride hexahydrate and triethylamine were purchased from Kanto Chemical CO. INC (Tokyo, Japan). Zinc nitrate was obtained from (BDH Chemicals Ltd pool England). FEX standard was obtained from the Quality Control Laboratory, Ministry of Health, Muscat, Sultanate of Oman.

Pharmaceutical formulations: Telfadin 180 mg (Muscat, Sultanate of Oman), Telfast 120 mg (France) and Fexodine 120 mg (Tabuk, Saudi Arabia) were purchased from local retail outlets.

2.3

2.3 Preparation of standard solutions

1.14 × 10−3 M of FEX stock standard solution was prepared in methanol. Working standard solutions were freshly prepared by appropriate dilutions of the stock with methanol.

Terbium (III) chloride hexahydrate stock solution (1.31 × 10−3 M) was prepared by dissolving 24.5 mg of Tb3+ in 50 mL methanol. Working standard solutions were freshly prepared by appropriate dilution of the stock solution with methanol. 2.00 × 10−3 M stock solution of triethylamine was prepared by dissolving 0.01 g of the reagent in 50 ml methanol.

Stock solutions (2.00 × 10−3 M) of various co-luminescent agents such as zinc nitrate, gadolinium, samarium, lanthanum, and europium were prepared in methanol.

2.4

2.4 Preparation of drug samples

Three commercial products containing known amounts of FEX were analyzed. Five tablets of each product were separately weighed, and then the tablets were powdered and mixed. A portion of the powder known to contain an equivalent amount of one tablet was accurately weighed and sonicated with methanol for 30 min. It was then filtered into a volumetric flask and completed to the mark with methanol to make a stock solution. Working solutions of 50 ppm in methanol were prepared. Appropriate aliquots from the working solution were taken for the determination of FEX in samples.

3

3 Results and discussion

3.1

3.1 Spectral characteristics

The absorption spectrum of FEX and Tb–FEX complex in methanol was found to exhibit two bands in the ultraviolet region at 202 nm and 219 nm. A slight enhancement in the absorption was observed in the presence of the complex when compared to the ligand alone.

On the other hand, the fluorescence spectrum of 1.0 × 10−5 M of FEX in methanol revealed a notable fluorescence signal in the low UV region with an emission wavelength at 298 nm when excited at 252 nm. The emission characteristic at low UV region will not be analytically useful particularly for the analysis of the drug in biological solution. This is due to the possible interference of short-life emitting species from the matrix.

In order to improve the analytical characteristics for the determination of FEX in pharmaceutical formulation, the system of (Tb–FEX) in methanol was investigated. FEX was used to sensitize the luminescence of terbium ion. Terbium exhibited a weak luminescence in methanol. However, when FEX was added to the Tb3+ solution, the intensity of Tb3+ peaks was enhanced about six times compared to that of Tb3+ alone as shown in Fig. 2. The signal of Tb–FEX resulted in the well-structured emission bands of Tb3+ while the excitation spectra of Tb3+ revealed the presence of a band at 216 nm. Upon addition of FEX to Tb3+ solution, a broad band slightly red shifted to 220 nm was observed (figure not shown).

Luminescence emission spectra of: (1) Tb3+ in MeOH system, (2) Tb3+ in presence FEX in MeOH. [Tb3+] = 2.3 × 10−6 M, [FEX] = 1.0 × 10−6 M, λex = 220 nm, λem = 550 nm.
Figure 2 Luminescence emission spectra of: (1) Tb3+ in MeOH system, (2) Tb3+ in presence FEX in MeOH. [Tb3+] = 2.3 × 10−6 M, [FEX] = 1.0 × 10−6 M, λex = 220 nm, λem = 550 nm.

The enhancement of the luminescence of Tb3+ ions upon addition of FEX is probably due to complexation of the ions by the drug with the ensuing efficient transfer of energy from FEX to the chelated Tb3+, which can overcome the low extinction coefficient of the ions. For efficient energy transfer to occur, the sensitizing moiety must absorb light in the ultraviolet region, which is the case for FEX. The close agreement between the absorption spectra of the ligand at 219 nm and the excitation spectra at 220 nm support that the excitation of the antenna may be the only photophysical pathway leading to the luminescence enhancement of the complex. Furthermore, a complete overlap between the absorption spectrum of FEX and the excitation spectrum of Tb–FEX complex is observed. The emission spectrum of Tb–FEX complex when excited by the π–π absorption band of the complex at 220 nm revealed the well-known bands of terbium luminescence. Among these transitions, the 5D47F5 around 545 nm is the strongest followed by the one at 490 nm. Therefore, the peak height at 550 nm was used to measure the luminescence intensity of the Tb–FEX complex. Moreover a large stokes shift of 330 nm was observed, indicating that there is no overlap between the Tb3+ emission band and the antenna chromophore absorption bands.

The luminescence intensity of Tb3+ at 550 nm is affected by the coordination environment. Hence the effect of solvent, concentration of Tb3+ and FEX, Et3N and Zn2+ and effect of different co-luminescence reagents were investigated in order to maximize the luminescence intensity.

3.2

3.2 Effect of solvent

The influence of the solvents on the luminescence intensity of FEX–Tb3+ complex was investigated carefully and the results are shown in Fig. 3. It can be seen that the enhancing effect of organic solvents in the Tb–FEX system is arranged in the order CH3OH > CH3CN > C2H5OH > C3H7OH > (CH3)2CO > H2O. The dielectric constants (ε) of these solvents are methanol 32.6, acetonitrile 37.5, ethanol 24.5, propanol 20.3, acetone 20.4 and water 78.8. It is clear that there is an agreement between dielectric constant (ε) of the solvents that contain oxygen atoms and the luminescence in the system apart from methanol and water. It has been reported, that the difference in intensity of the emission line between the four alcoholic solutions indicates the different coordination behavior of alcohols with terbium metal with methanol exhibiting the strongest coordination ability (AbdEl-Hay et al., 2012). Similar results were previously reported for terbium and europium complexes, where maximum sensitization was observed in the presence of methanol (Al-Kindy et al., 2008; Dang et al., 2007; Qin et al., 2003). The emission intensity decreases with increase in the alkyl chain in alcohols (Ansari et al., 2007). The low sensitization in water may be due to the O–H oscillators of water molecules that are known to quench the excited state of the lanthanide ions by interaction with high-energy vibrations associated with O–H. Solvent molecules can usually replace coordinated water and avoid high frequency O–H bond vibration—thus greatly decreasing energy loss resulting through the coordination of water molecules, and increasing the fluorescence intensity of the emitting lanthanide ion. This suggests that the chemical environment plays an important role in determining the fluorescence intensity of the complexes; hence, the choice of methanol was ideal in studying the luminescence of the Tb–FEX complex.

Effect of type of solvent on terbium sensitized luminescence emission spectra. [FEX] = 1.03 × 10−5 M, [Tb3+] = 2.89 × 10−5 M, λex = 220 nm, λem = 550 nm (1) methanol, (2) acetonitrile, (3) ethanol, (4) propanol, (5) acetone, and (6) water.
Figure 3 Effect of type of solvent on terbium sensitized luminescence emission spectra. [FEX] = 1.03 × 10−5 M, [Tb3+] = 2.89 × 10−5 M, λex = 220 nm, λem = 550 nm (1) methanol, (2) acetonitrile, (3) ethanol, (4) propanol, (5) acetone, and (6) water.

3.3

3.3 Stoichiometry of the Tb–FEX complex

Since the sensitization results from complex formation between FEX and Tb3+, it is necessary to optimize the ratio of the concentration of the metal to the ligand that will result in maximum complexation and hence maximum intensity of the emission line of terbium ion. The optimum concentration of terbium was determined by measuring the luminescence intensity of various molar ratios of Tb3+:FEX. The luminescence intensity increased with an increased concentration of FEX and reached a maximum value at a ratio of 1:3 after which the intensity remained constant (Fig. 4) indicating the formation of Tb (FEX)3 complex.

Influence of [FEX]: [Tb3+] ratio on terbium sensitized luminescence. [Tb3+] = 1 × 10−5 M, λex = 220 nm. λem = 550 nm.
Figure 4 Influence of [FEX]: [Tb3+] ratio on terbium sensitized luminescence. [Tb3+] = 1 × 10−5 M, λex = 220 nm. λem = 550 nm.

The stoichiometry of the complex was corroborated using Job’s plot of continuous variation. Equal concentration of Tb3+ and FEX (2.0 × 10−5 M) was used, and the molar ratio of Tb3+:FEX was varied. The luminescence intensity increased with an increase in the mole fraction of Tb3+:FEX and reached a maximum at a mole fraction of 0.3 (Fig. 5), indicating a stoichiometry of Tb3+:FEX of 1:3.

Continuous variation method of the Tb (FEX) complex in MeOH. [Tb3+] = [FEX] = 2.0 × 10−5 M, λem = 550 nm, λex = 220 nm.
Figure 5 Continuous variation method of the Tb (FEX) complex in MeOH. [Tb3+] = [FEX] = 2.0 × 10−5 M, λem = 550 nm, λex = 220 nm.

3.4

3.4 Luminescence enhancement of Tb–FEX complex by zinc and Et3N

One of the strategies to improve the luminescence of lanthanide system is the addition of co-luminescence agent. Non-fluorescing lanthanide ions such as La3+, Gd3+ and Lu3+ have been used. In the presence of these ions, the fluorescence of Tb3+ and Eu3+ complexes is enhanced (Yang et al., 1994). In this case, the intermolecular energy flow is believed to occur between the non-fluorescing donor complexes of Ln3+, Gd3+ and Sm3+ to the fluorescing acceptor complexes of Tb3+, Eu3+ or Dy3+.

Initially the effect of addition of co-luminescence agents such as Eu3+, La3+, Gd3+, Sm3+ and Zn2+ with the concentration of 5.00 × 10−6 M was investigated. Addition of Zn2+ gave the highest luminescence intensity in this system. However, other co-luminescence quenched the fluorescence of Tb3+ as shown in Fig. 6.

The effect of co-luminescence agents on the luminescence spectra of Tb3+–FEX system. [Tb3+] = 2.25 × 10−6 M, [FEX] = 7.5 × 10−7 M, [co-luminescence] = 5.00 × 10−6 M.
Figure 6 The effect of co-luminescence agents on the luminescence spectra of Tb3+–FEX system. [Tb3+] = 2.25 × 10−6 M, [FEX] = 7.5 × 10−7 M, [co-luminescence] = 5.00 × 10−6 M.

Most of the work on co-luminescence effect was reported in aqueous system in the presence of micelles and synergistic agents such as TOPO or 1, 10 phenanthroline. Recently, (Dang et al., 2007) a new co-luminescence system was reported in methanol, the system used β-diketonate as ligand. The system of Tb-N-(2-pyridinyl) ketoacetamide was greatly enhanced in the presence of zinc nitrate and triethylamine (Et3N).

In this study, the luminescence properties of Tb–FEX complex were enhanced in the presence of Zn2+ and Et3N (Fig. 7). It is clear from the figure that Tb3+ exhibited a weak signal in methanol. When adding Et3N and FEX an enhancement of the terbium ion signal is observed. However, a huge enhancement in the signal is observed when Zn2+ was added to Tb3+ in the presence of FEX and Et3N.

The emission spectra of Tb–FEX–Et3N–Zn (1), Tb–FEX–Et3N, (2), Tb–FEX, (3) Tb3+ alone, (4) system in methanol. [Tb3+] = 2.25 × 10−6 M, [FEX] = 7.50 × 10−7 M, [Et3N] = 5.00 × 10−6 M and [Zn2+] = 5.00 × 10−6 M.
Figure 7 The emission spectra of Tb–FEX–Et3N–Zn (1), Tb–FEX–Et3N, (2), Tb–FEX, (3) Tb3+ alone, (4) system in methanol. [Tb3+] = 2.25 × 10−6 M, [FEX] = 7.50 × 10−7 M, [Et3N] = 5.00 × 10−6 M and [Zn2+] = 5.00 × 10−6 M.

Many multinuclear heterometallic 3d–4f complexes were reported (Towatari et al., 2013; Lü et al., 2010; Yang et al., 2005; Bi et al., 2009). The formation of these complexes was evidenced by characterization by X-ray crystallography which revealed the existence of functional bridge in these 3d–4f complexes. The donation of OH groups was the main facilitator of the formation of such complexes. In the coordination compounds involving Zn2+ and lanthanide ions, it was reported that complexation of a pyridine group to Zn2+ ions in these complexes resulted in congestion around the coordination sphere of the 4f Ln3+ ions (Bi et al., 2009). This has led to a significant minimization of the luminescence quenching from solvents molecules around the lanthanide ions. On the other hand, the involvement of heavy atoms in the structure improves the antenna energy transfer significantly. We believe that a similar mechanism might be responsible for the enhancement of the luminescence of Tb3+–ZN Et3N.

However, further work needs to be done to explain the actual mechanism of the energy transfer, including synthesizing the complex in a large scale and verify it is structured by X-ray crystallography.

Moreover, the influence of the amount of Et3N on the fluorescence intensity was studied. The maximum intensity of luminescence was at the concentration of Et3N equal to 5.0 × 10−6 M. Therefore, 5.0 × 10−6 M was employed as the final Et3N concentration.

After optimizing the concentration of Et3N, the effect of concentration of Zn2+ on the system was investigated. The luminescence intensity increased with an increase in the concentration of zinc and maximum intensity was observed at a concentration 5.0 × 10−6 M of zinc. On increasing the concentration of zinc further, a decrease in the luminescence intensity was observed. This could be due to the fact that a large excess of Zn ions could result in favoring the formation of mononuclear Zn-complexes at the expense of the heteronuclear metallic complexes. Hence, a 5.0 × 10−6 M of Zn2+solution was used for the subsequent work.

3.5

3.5 Effect of Tb3+ concentration

The effect of Tb3+ concentration on the luminescence intensity of the system was examined after optimizing all the other parameters. The luminescence intensity starts to increase with an increase in the concentration of Tb3+ until it reaches the maximum at 2.25 × 10−6 M after which a decrease in the luminescence intensity was observed. Hence, an optimum concentration of terbium for this study was taken to be a concentration of 2.25 × 10−6 M.

3.6

3.6 Analytical appraisal

A series of standard solutions of FEX (0–1000 ppb) were analyzed by the proposed method. The obtained calibration curves were evaluated using linear regression methods. The luminescence intensity I, versus FEX concentration was found to be linear over the range 10–800 ppb. The calibration equation was I = 974.6 C–0.566, with a correlation coefficient R2 of 0.9999. The detection limit (S/N ratio = 3) was 1.00 ppb. The lower limit of quantitation (S/N = 10) was 4.00 ppb. The reproducibility of the method was obtained for standard solutions of FEX of 200 ppb and was found to be less than 2% (n = 7).

In the presence of Zn2+ and Et3N, the luminescence intensity I, versus FEX concentration was also found to be linear over the range 10–800 ppb. The calibration equation was: I = 1994 C + 0.108, with a correlation coefficient R2 of 0.999. Lower detection and quantitation limits of 0.3 ppb and 1.00 ppb were obtained respectively. The figures of merit of the proposed method compared favorably with most of the published methods for the determination of FEX (Table 1). In addition, the method offered an advantage over other luminescence methods, in that its emission is at a longer wavelength and free from interference from short-life emitting species present in these matrices.

Table 1 Comparison with other methods for the determination of fexofenadine.
Method Linear range (μg mL−1) LOD (μg mL−1) References
HPLC with UV detection 24–120 0.283 Pankaniya et al. (2013)
HPLC with UV detection 5–40 0.27 Krakus et al. (2008)
CE (UV detection) 20–100 0.69 Breier et al. (2005)
HPLC with Fluorescence 0.001–0.5 1.0 × 10−3 Uno et al., 2004
HPLC with Fluorescence 0.005–0. 8 5.0 × 10−3 Konieczna et al., 2010
Spectrofluorimetry 0.05–12.5 0.006 Alothman et al. (2010)
Spectrofluorimetry 0.2–3.5 0.14 Eid and Wahba (2012)
LC–MS/MS 0.001–0.6 Guo et al. (2010)
MF–CL 0.05–5.0 0.001 Al-Lawati et al. (2011)
This work 0.01–0.8 0.0003

3.7

3.7 Determination of FEX in pharmaceutical preparations

The proposed method was applied for the determination of the concentration of FEX in pharmaceutical formulations of different bands as shown in Table 2. The tablets are known to contain many excipients as fillers or binder. Three samples were prepared as described above and were analyzed by the proposed method. It is clear from the results that good recovery with no interference from the excipients was obtained indicating that the method exhibits good selectivity. For comparison, FEX in the pharmaceutical formulation was determined using a spectrofluorimetric method (Ibrahim et al., 2011). These determinations were carried out on the same batch of samples. The results obtained were compared statistically using Student t-test and the F-test (Table 3). Both methods produced comparable accuracy and precision, which indicates that there is no significant difference between the two methods.

Table 2 Determination of FEX in pharmaceutical samples using the proposed procedure (n = 7).
Formulation Claimed (mg) Amount found ± SD (mg) Recovery% ± RSD
Telfadin 180.0 180.2 ± 3.2 100.1 ± 1.8
Fexodine 120.0 122.5 ± 2.2 102.1 ± 1.8
Telfast 120.0 119.0 ± 3.1 99.1 ± 2.6
Table 3 Determination of FEX in pharmaceutical sample by FL method (n = 7).
Formulation Claimed (mg) Amount found ± SD (mg) Recovery% ± RSD t-test F-test
Telfadin 180.0 179.3 ± 1.7 99.6 ± 0.9 0.025 3.54
Fexodine 120.0 119.3 ± 2.4 99.4 ± 2.0 0.097 1.19
Telfast 120.0 117.1 ± 1.6 97.6 ± 1.4 0.584 3.75

Confidence limit at p = 0.05 and six degrees of freedom (df) (t = 2.365).

Tabulated F-value for p = 0.05 and df1 = df2 = 6 (4.28).

4

4 Conclusion

In this study, a sensitive and selective method was successfully developed for the assay of FEX in pharmaceutical preparations. The proposed method was based on sensitized terbium time resolved luminescence. The enhancement of the terbium luminescence upon complexation with FEX has enabled the assay of this drug with high sensitivity and selectivity where short-lived emissions were efficiently eliminated. The procedure was applied for the determination of FEX in various tablets with excellent recoveries and reproducibility. The proposed method has the advantage of being simpler, more rapid, and suitable for automation. It is sensitive to the low amount of fexofenadine. As a result, the proposed method represents excellent analytical alternative for the determination of fexofenadine in pharmaceutical formulations. Further work needs to be done to study the terbium-sensitized luminescence in aqueous system. This will enable monitoring of FEX in biological fluid.

Acknowledgment

The financial support from Department of Chemistry Sultan Qaboos University is greatly appreciated.

References

  1. , , , , . Spectrofluorimetric determination of etodolac, moxepril hydrochloride and fexofenadine hydrochloride using europium sensitized fluorescence in bulk and pharmaceutical preparations. J. Fluoresc.. 2012;22:247-252.
    [Google Scholar]
  2. , , . Determination of ibuprofen in pharmaceutical formulations using terbium sensitized luminescence. Luminescence. 2007;22:294-301.
    [Google Scholar]
  3. , , , . A sequential injection method for the determination of piroxicam in pharmaceutical formulations using europium sensitized fluorescence. Talanta. 2004;64:1343-1350.
    [Google Scholar]
  4. , , , , , . Determination of piroxicam in pharmaceutical formulations and urine samples using europium-sensitized luminescence. J. Lumin.. 2007;127:291-296.
    [Google Scholar]
  5. , , , , , . Terbium sensitized luminescence for the determination of ketoprofen in pharmaceutical formulations. J. Fluoresc.. 2008;19:245-299.
    [Google Scholar]
  6. , , , , . Determination of meloxicam using europium sensitized luminescence in the presence of co-luminescence reagents. J. Fluoresc.. 2012;22:467-474.
    [Google Scholar]
  7. , , , , , . Analysis of fexofenadine in pharmaceutical formulations using tris(1,10-phenanthroline)- ruthenium(II) peroxydisulphate chemiluminescence system in a multichip device. Lumin. J.. 2011;26:762-767.
    [Google Scholar]
  8. , , , , , . Spectrofluorimetric determination of fexofenadine hydrochloride in pharmaceutical preparation using silver nanoparticles. Arabian J. Chem.. 2010;3:251-255.
    [Google Scholar]
  9. , , , , , . Solvent effect on optical properties of hydrated lanthanide tris–acetylacetone. J Lumin.. 2007;127:446-452.
    [Google Scholar]
  10. , , , . Extractive spectrophotometric and conductometric methods for determination of fexofenadine hydrochloride in pharmaceutical dosage. Pharm. Anal. Acta S. 2013;2:003.
    [CrossRef] [Google Scholar]
  11. , , , , , , , . Hetero-trinuclear near-infrared (NIR) luminescent Zn2Ln complexes from Salen-type Schiff-base ligands. New J. Chem.. 2009;33:2326-2334.
    [Google Scholar]
  12. , , , , , . Capillary electrophoresis method for fexofenadine hydrochloride in capsules. J. AOAC Int.. 2005;88:1059-1063.
    [Google Scholar]
  13. , , , . The new fluorescence enhancement system Tb-N-(2-pyridinyl) ketoacetamide-Et3N-Zn and its application. Spectrochim. Acta A. 2007;66:676-680.
    [Google Scholar]
  14. , , . Validated spectrofluorimetric determination of some H1-receptor antagonists drugs in pharmaceutical preparations through charge transfer complexation. J. Fluoresc.. 2012;22:175-191.
    [Google Scholar]
  15. , , , , , . Determination of some histamine H1-receptor antagonists in dosage forms. J. Pharm. Biomed.. 2002;15:859-867.
    [Google Scholar]
  16. , , , , , , . Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC–MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. Biomed. Chromatogr.. 2010;24:335-341.
    [Google Scholar]
  17. , , , , . Determination of fexofenadine in human plasma and urine by liquid chromatography-mass. J. Chromatogr. B. 2002;766:227-233.
    [Google Scholar]
  18. , , , , . Spectrofluorimetric determination of some H1-receptor antagonists drugs in pharmaceutical formulations and biological fluids. IJPSR. 2011;2(8):2056-2072.
    [Google Scholar]
  19. , , . Effect of standard medication on quality of life of patients with atopic dermatitis. J. Dermatol.. 2007;34:9-16.
    [Google Scholar]
  20. , , , , , . Rapid RP-LC method with fluorescence detection for analysis of fexofenadine in human plasma. Chromatographia. 2010;71:1081-1086.
    [Google Scholar]
  21. , , , . Development and validation of a rapid RP- HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms. J. Pharm. Biomed.. 2008;46:295-302.
    [Google Scholar]
  22. , , , , , , , , , . Near-infrared luminescent, neutral, cyclic Zn2 Ln2 (Ln = Nd, Yb, and Er) complexes from asymmetric Salen-type Schiff base ligands. Eur. J. Inorg. Chem. 2010:2714-2722.
    [Google Scholar]
  23. , , . Efficacy and safety profile of fexofenadine HCl A unique therapeutic option in H1-receptor antagonist treatment. J. Allergy Clin. Immunol.. 2003;112:S69-S77.
    [Google Scholar]
  24. , , , . Determination of fexofenadine in tablets by capillary electrophoresis in free solution and in solution with cyclodextrins as analyte carriers. Drug Dev. Ind. Pharm.. 2005;31:795-801.
    [Google Scholar]
  25. , , . A new method for the spectrophotometric determination of fexofenadine hydrochloride. Indian J. Technol.. 2010;17:386-390.
    [Google Scholar]
  26. , , , . Stability-indicating HPLC method for simultaneous determination of Montelukast and fexofenadine hydrochloride. Indian J. Pharm. Sci.. 2013;75(3):284-290.
    [Google Scholar]
  27. , , , , . Synthesis and infrared and fluorescence spectral properties of luminescent terbium and europium complexes with open – chain–chain carboxylate crown ethers. Spectrochim. Acta A. 2003;59:3085-3092.
    [Google Scholar]
  28. , , . Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000;59:301-321.
    [Google Scholar]
  29. , , , , , , , , , , . Syntheses, structures, and magnetic properties of acetato- and diphenolato-bridged 3d–4f binuclear complexes [M(3-MeOsaltn)(MeOH)x(ac)Ln(hfac)2] (M = ZnII, CuII, NiII, CoII; Ln = LaIII, GdIII, TbIII, DyIII; 3-MeOsaltn = N, N′-Bis(3-methoxy-2-oxybenzylidene)-1,3-propanediaminato; ac = Acetato; hfac = hexafluoroacetylacetonato; x = 0 or 1) Inorg. Chem.. 2013;52:6160-6178.
    [Google Scholar]
  30. , , , , , . Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J. Pharm. Biomed.. 2004;35:937-942.
    [Google Scholar]
  31. , , , , , , . Study on the co- luminescence system Sm-Gd–BPMPHD–CTMAB and its analytical application. Fres. J. Anal. Chem.. 1994;349:728-733.
    [Google Scholar]
  32. , , , , , . Synthesis and near infrared luminescence of a tetrametallic Zn2Yb2 architecture from a trinuclear Zn3L2 Schiff base complex. Dalton Trans. 2005:849-851.
    [Google Scholar]

Appendix A

Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.arabjc.2015.01.016.

Appendix A

Supplementary material

Supplementary Figure 1

Show Sections